日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC

应激激活的STK24调控的MASTL/YBX1/PAK4轴可引发肝细胞癌中的乐伐替尼耐药性和肿瘤进展。

期刊:Hepatology
影响因子:15.8
doi:10.1097/HEP.0000000000001392
Liang, Bu-Gang; Zheng, Yi-Min; Xu, Ming-Hao; Gao, Chao; Xu, Wen-Xin; Chen, Jun-Bo; Wang, Si-Wei; Zhao, Long-Tao; Yang, Guo-Huan; Yuan, Li; Ma, A-Ying; Dong, Ze-Ning; Cai, Jia-Bin; Sun, Hui-Chuan; Ke, Ai-Wu; Shen, Ying-Hao
PAK4
肿瘤
MASTL
肿瘤免疫
信号转导
ASTL
STK24
细胞生物学
发表日期：2026
文献求助 收藏

Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma

对于潜在可切除的肝细胞癌，免疫治疗后病情稳定且肿瘤未缩小的患者无法从手术中获益。

期刊:Liver Cancer
影响因子:9.1
doi:10.1159/000550497
He, Tian; Xu, Bin; Yang, Zi-Yue; Zhou, Shi-Qi; Wang, Zi-Yi; Wang, Lu-Na; Zhong, Cheng-Jie; Shi, Huan-Chen; Li, Hui; Hu, Bo; Zhu, Xiao-Dong; Shen, Ying-Hao; Gao, Qiang; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan; Huang, Cheng
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2026
文献求助 收藏

CXCL6 Reshapes Lipid Metabolism and Induces Neutrophil Extracellular Trap Formation in Cholangiocarcinoma Progression and Immunotherapy Resistance.

CXCL6 重塑脂质代谢，诱导中性粒细胞胞外陷阱形成，从而导致胆管癌进展和免疫治疗耐药

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202503009
He Tian, Wang Zi-Yi, Xu Bin, Zhong Cheng-Jie, Wang Lu-Na, Shi Huan-Chen, Yang Zi-Yue, Zhou Shi-Qi, Li Hui, Hu Bo, Zhu Xiao-Dong, Shen Ying-Hao, Zhou Jian, Fan Jia, Sun Hui-Chuan, Huang Cheng
代谢
发表日期：2025
文献求助 收藏

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy

系统性免疫炎症指数在接受免疫疗法治疗的不可切除肝细胞癌患者中的预后价值

期刊:Biomarker Research
影响因子:11.5
doi:10.1186/s40364-024-00722-6
He, Tian; Xu, Bin; Wang, Lu-Na; Wang, Zi-Yi; Shi, Huan-Chen; Zhong, Cheng-Jie; Zhu, Xiao-Dong; Shen, Ying-Hao; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan; Hu, Bo; Huang, Cheng
肿瘤
炎症
肿瘤免疫
炎症/感染
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Depth of Radiographic Response as an Independent Prognostic Factor for Patients with Initially Unresectable Hepatocellular Carcinoma Receiving Hepatectomy following Targeted Therapy plus Immunotherapy

放射学反应深度是接受靶向治疗联合免疫治疗后行肝切除术的初始不可切除肝细胞癌患者的独立预后因素

期刊:Liver Cancer
影响因子:9.1
doi:10.1159/000541300
Xu, Bin; Wang, Lu-Na; Wang, Zi-Yi; He, Tian; Zhu, Xiao-Dong; Shen, Ying-Hao; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan; Huang, Cheng
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancer

赖氨酸特异性去甲基化酶1缺失重塑肿瘤微环境，从而克服肝癌中对程序性死亡受体1抑制剂治疗的获得性耐药性

期刊:Clinical and Translational Medicine
影响因子:6.8
doi:10.1002/ctm2.70335
Liang, Chen; Ye, Mu; Yu, Lei; Zhang, Peng-Fei; Guo, Xiao-Jun; Meng, Xian-Long; Zeng, Hai-Ying; Hu, Shu-Yang; Zhang, Dao-Han; Sun, Qi-Man; Shen, Ying-Hao; Cai, Jia-Bin; Li, Shuang-Qi; Chen, Zhen; Shi, Ying-Hong; Ke, Ai-Wu; Shi, Yujiang G; Zhou, Jian; Fan, Jia; Wu, Fei-Zhen; Huang, Xiao-Yong; Shi, Guo-Ming; Tang, Zheng; Lu, Jia-Cheng
肿瘤
表观遗传
肿瘤免疫
信号转导
肝癌
肿瘤微环境
发表日期：2025
文献求助 收藏

Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma

对不可切除的肝细胞癌患者进行酪氨酸激酶抑制剂联合抗PD-1抗体治疗后的转化疗法后行肝切除术

期刊:Annals of Surgical Oncology
影响因子:3.5
doi:10.1245/s10434-022-12530-z
Zhu, Xiao-Dong; Huang, Cheng; Shen, Ying-Hao; Xu, Bin; Ge, Ning-Ling; Ji, Yuan; Qu, Xu-Dong; Chen, Lingli; Chen, Yi; Li, Mei-Ling; Zhu, Jin-Jin; Tang, Zhao-You; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan
肿瘤
肿瘤免疫
信号转导
细胞生物学
PD-1
发表日期：2023
文献求助 收藏

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study

放射学和甲胎蛋白反应预测肝细胞癌免疫疗法联合酪氨酸激酶抑制剂治疗后的病理完全缓解：一项多中心研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-023-10898-z
Huang, Cheng; Zhu, Xiao-Dong; Shen, Ying-Hao; Xu, Bin; Wu, Dong; Ji, Yuan; Chen, Ling-Li; Song, Tian-Qiang; Zhang, Wei; Zeng, Zhi-Ming; Huang, Hua-Sheng; Wang, Kui; Huang, Lan-Qing; Chen, Yong-Jun; Yang, Yu-Chen; Zhou, Le-Du; Long, Guo; Zhao, Hai-Tao; Wang, Yun-Chao; Ge, Ning-Ling; Chen, Yi; Tan, Chang-Jun; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan
肿瘤
肿瘤免疫
信号转导
细胞生物学
免疫/内分泌
发表日期：2023
文献求助 收藏

Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study

乐伐替尼联合抗程序性死亡受体-1抗体治疗肝细胞癌患者的有效性和安全性：一项真实世界队列研究

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.5661
Xu, Ming-Hao; Huang, Cheng; Li, Mei-Ling; Zhu, Xiao-Dong; Tan, Chang-Jun; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan; Shen, Ying-Hao
信号转导
细胞生物学
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Peripheral naïve CD8(+) T cells as a predictive biomarker of response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a biomarker study

外周幼稚CD8(+) T细胞作为晚期肝细胞癌患者接受乐伐替尼联合抗PD-1抗体治疗疗效的预测性生物标志物：一项生物标志物研究

期刊:Cancer Communications
影响因子:24.9
doi:10.1002/cac2.12350
Huang, Cheng; Xu, Bin; Zhu, Xiao-Dong; Shen, Ying-Hao; Li, Mei-Ling; Zhu, Jin-Jin; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan
肿瘤
T细胞
肿瘤免疫
CD8
T细胞
细胞生物学
PD-1
免疫/内分泌
发表日期：2022
文献求助 收藏